RT Journal Article
SR Electronic
T1 Stratifying Lung Adenocarcinoma Risk with Multi-ancestry Polygenic Risk Scores in East Asian Never-Smokers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.26.24309127
DO 10.1101/2024.06.26.24309127
A1 Blechter, Batel
A1 Wang, Xiaoyu
A1 Shi, Jianxin
A1 Shiraishi, Kouya
A1 Choi, Jiyeon
A1 Matsuo, Keitaro
A1 Chen, Tzu-Yu
A1 Dai, Juncheng
A1 Hung, Rayjean J
A1 Chen, Kexin
A1 Shu, Xiao-Ou
A1 Kim, Young Tae
A1 Choudhury, Parichoy Pal
A1 Williams, Jacob
A1 Landi, Maria Teresa
A1 Lin, Dongxin
A1 Zheng, Wei
A1 Yin, Zhihua
A1 Song, Bao
A1 Chang, I-Shou
A1 Hong, Yun-Chul
A1 ,
A1 ChaVerjee, Nilanjan
A1 Gorlova, Olga Y
A1 Amos, Christopher I
A1 Shen, Hongbing
A1 Hsiung, Chao Agnes
A1 Chanock, Stephen J
A1 Rothman, Nathaniel
A1 Kohno, Takashi
A1 Lan, Qing
A1 Zhang, Haoyu
YR 2024
UL http://medrxiv.org/content/early/2024/06/27/2024.06.26.24309127.abstract
AB Background Lung adenocarcinoma (LUAD) among never-smokers is a public health burden especially prevalent in East Asian (EAS) women. Polygenic risk scores (PRSs), which quanefy geneec suscepebility, are promising for straefying risk, yet have mainly been developed in European (EUR) populaeons. We developed and validated single-and mule-ancestry PRSs for LUAD in EAS never-smokers, using the largest available genome-wide associaeon study (GWAS) dataset.Methods We used GWAS summary staesecs from both EAS (8,002 cases; 20,782 controls) and EUR (2,058 cases; 5,575 controls) populaeons, as well as independent EAS individual level data. We evaluated several PRSs approaches: a single-ancestry PRS using 25 variants that reached genome-wide significance (PRS-25), a genome-wide Bayesian based approach (LDpred2), and a mule-ancestry approach that models geneec correlaeons across ancestries (CT-SLEB). PRS performance was evaluated based on the associaeon with LUAD and AUC values. We then esemated the lifeeme absolute risk of LUAD (age 30-80) and projected the AUC at different sample sizes using EAS-derived effect-size distribueon and heritability esemates.Findings The CT-SLEB PRS showed a strong associaeon with LUAD risk (odds raeo=1.71, 95% confidence interval (CI): 1.61, 1.82) with an AUC of 0.640 (95% CI: 0.629, 0.653). Individuals in the 95th percenele of the PRS had an esemated 6.69% lifeeme absolute risk of LUAD. Comparison of LUAD risk between individuals in the highest and lowest 20% PRS quaneles revealed a 3.92-fold increase. Projeceon analyses indicated that achieving an AUC of 0.70, which approaches the maximized prediceon poteneal of the PRS given the esemated geneec variance, would require a future study encompassing 55,000 EAS LUAD cases with a 1:10 case-control raeo.Interpretations Our study underscores the poteneal of mule-ancestry PRS approaches to enhance LUAD risk straeficaeon in never-smokers, parecularly in EAS populaeons, and highlights the necessary scale of future research to uncover the geneec underpinnings of LUAD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDetails of the funding statement are provided in the acknowledgment section of the manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the National Cancer Center Institutional gave ethical approval for this work Ethics committee/IRB of Japan and the Aichi Cancer Center Ethics Committee, Japan gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data supporting the findings described in this paper are available in the paper and in the Supplementary Information and from the corresponding author or as otherwise indicated upon request. The individual genotype data for the FLCCA data are in dbGaP phs000716.v1.p1 (Genome-Wide Association Study of Lung Cancer Susceptibility in Never-Smoking Women in Asia). For the NCC and ACC studies, please contact Kouya Shiraishi at kshirais{at}ncc.go.jp or Takashi Kohno at tkkohno{at}ncc.go.jp for summary statistics. The GWAS data for the European populations contributing to this study are available at dbGap under accession phs000877.v1.p1 (Transdisciplinary Research Into Cancer of the Lung (TRICL), https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000876.v2.p1), phs001273.v3.p2 (Oncoarray Consortium, https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001273.v3.p2). To gain access to all data in dbGaP cited in this paper, please apply for dbGaP Authorized Access. GWAS data for the European populations contributing to this study are available under accession phs000877.v1.p1 (ILLCO), phs001273.v1.p1 (OncoArray).